Stockscreener 앱 받기
76.55
0.78%
-0.60
시장 영업 전:
79.17
2.62
+3.42%
전일 마감가:
$77.15
열려 있는:
$77.56
하루 거래량:
917.02K
Relative Volume:
0.49
시가총액:
$10.78B
수익:
$622.01M
순이익/손실:
$-271.86M
주가수익비율:
-35.63
EPS:
-2.1484
순현금흐름:
$-45.87M
1주 성능:
+4.39%
1개월 성능:
-0.16%
6개월 성능:
+18.39%
1년 성능:
+387.58%
1일 변동 폭
$74.79
$78.09
1주일 범위
$69.51
$78.09
52주 변동 폭
$14.30
$82.26
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
명칭
Arrowhead Pharmaceuticals Inc
전화
626-696-4702
주소
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
76.55 | 10.87B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 개시 | Goldman | Neutral |
| 2023-12-04 | 개시 | BofA Securities | Buy |
| 2023-09-19 | 개시 | Citigroup | Neutral |
| 2023-07-21 | 개시 | TD Cowen | Outperform |
| 2023-05-12 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-12 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 재개 | Goldman | Buy |
| 2021-08-06 | 재확인 | Chardan Capital Markets | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-19 | 개시 | Citigroup | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-05-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 개시 | Goldman | Neutral |
| 2020-01-21 | 개시 | SVB Leerink | Underperform |
| 2019-12-13 | 개시 | Oppenheimer | Perform |
| 2019-11-29 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-27 | 재확인 | B. Riley FBR | Buy |
| 2019-11-25 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 재확인 | Chardan Capital Markets | Buy |
| 2019-10-03 | 개시 | Robert W. Baird | Outperform |
| 2018-09-07 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-08-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 재확인 | Chardan Capital Markets | Buy |
모두보기
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Why (ARWR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits
WEALTH EFFECTS LLC's Arrowhead Pharmaceuticals Inc(ARWR) Holding History - GuruFocus
Arrowhead Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Arrowhead Pharmaceuticals lines up SHASTA readout as REDEMPLO launch gains traction - MSN
Alpha-1 Antitrypsin Deficiency Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Grifols, Kamada Pharma, Takeda, Arrowhead Pharma, Mereo BioPharma, AstraZeneca, Sanofi - Barchart.com
Arrowhead Pharmaceuticals, Inc. Trade Ideas — XETR:HDP1 - TradingView
Net income of Arrowhead Pharmaceuticals, Inc. – XETR:HDP1 - TradingView
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction - Yahoo Finance
Q3 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Arrowhead Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Arrowhead Pharmaceuticals Inc (BSP:A2RR34) Competitors 2026 - GuruFocus
Q4 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Arrowhead Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript - GuruFocus
Arrowhead Pharmaceuticals Inc Stock Baskets | BSP:A2RR34 - GuruFocus
Arrowhead Pharmaceuticals Inc (BSP:A2RR34) Stock News, Headlines & Updates - GuruFocus
Arrowhead Pharmaceuticals Inc Stock Warning Signs - GuruFocus
Arrowhead Pharmaceuticals Inc (BSP:A2RR34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Arrowhead Pharmaceuticals Inc (BSP:A2RR34) Stock Price & 30 Year Financial Data - GuruFocus
Arrowhead Pharmaceuticals Inc (BSP:A2RR34) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Arrowhead Pharmaceuticals Inc Stock Operating Data - GuruFocus
Homozygous Familial Hypercholesterolemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics - Barchart
Understanding Momentum Shifts in (ARWR) - Stock Traders Daily
Arrowhead Pharmaceuticals Prepares for Key Healthcare Conferences - GuruFocus
Arrowhead Pharmaceuticals Drops 7.0% Amid Sector-Wide Selling - AlphaStreet
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events - BioSpace
Arrowhead Pharmaceuticals eyes Q3 SHASTA data as REDEMPLO approvals build momentum - MSN
ViaSat, Arrowhead Pharmaceuticals, and SiTime Lead Stocks with High Returns - Markets Mojo
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After New Plozasiran And ARO INHBE Clinical Results - Sahm
Arrowhead Pharmaceuticals (ARWR) Reveals Promising Interim Trial Results - GuruFocus
Arrowhead presents trial data for obesity treatment candidate - Investing.com UK
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 - Arrowhead Pharmaceuticals, Inc.
Arrowhead presents trial data for obesity treatment candidate By Investing.com - Investing.com Canada
Arrowhead presents new positive clinical data on plozasiran - The Pharma Letter
Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus - Yahoo Finance
Arrowhead Pharmaceuticals (ARWR) Reports Clinical Findings for P - GuruFocus
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress - BioSpace
Arrowhead presents plozasiran data on renal, hepatic impairment - Investing.com UK
Arrowhead presents plozasiran data on renal, hepatic impairment By Investing.com - Investing.com Nigeria
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026 - Insider Monkey
Avoiding Lag: Real-Time Signals in (ARWR) Movement - Stock Traders Daily
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
ARROWHEAD PHARMACEUTICALS IN (ARWR) Technical Analysis - ChartMill
Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Arrowhead’s ARO-CFB Kidney Trial Completion: What Investors Should Watch Next - TipRanks
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum - Barchart.com
Arrowhead Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Director Daniel Apel to offer 100,000 ARWR common shares (NASDAQ: ARWR) - Stock Titan
Insider Hongbo Lu notifies sale of 2,970 ARWR shares (NASDAQ: ARWR) - Stock Titan
James Hamilton to sell 10,000 shares (ARWR) after prior 10,000-share sale - Stock Titan
Arrowhead Pharmaceuticals eyes $4B Redemplo opportunity as RNAi pipeline readouts near - MSN
Arrowhead Pharmaceuticals Inc (ARWR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):